Treating acute coronary syndromes with new antiplatelet drugs: The mortality issue with prasugrel and ticagrelor

Stefano De Servi, Eliano Pio Navarese, Maurizio D'Urbano, Stefano Savonitto

Research output: Contribution to journalArticlepeer-review

Abstract

Acute coronary syndromes (ACS) are the leading cause of mortality in Western countries. Until a few years ago, the antiplatelet drug to be administered in association with aspirin was indisputably clopidogrel. Recent data from randomized trials conducted in ACS patients have shown that the new oral antiplatelet regimens, prasugrel and ticagrelor, are associated with a significant reduction in cardiovascular events, as compared to clopidogrel. Moreover ticagrelor reduced both all-cause and cardiovascular mortality as compared to clopidogrel in the PLATO trial. However, there are intrinsic differences between the trials design and among the enrolled ACS populations, that make complex the generalization of the mortality results in the whole spectrum of ACS patients. We aimed to provide further insights into the unresolved mortality issues raised in the PLATO and TRITONTIMI 38 trials, by analysing the effects of ticagrelor and prasugrel in the ACS populations included in the respective trials.

Original languageEnglish
Pages (from-to)2117-2122
Number of pages6
JournalCurrent Medical Research and Opinion
Volume27
Issue number11
DOIs
Publication statusPublished - Nov 2011

Keywords

  • Acute coronary syndromes
  • Mortality
  • New antiplatelet drugs
  • Randomized studies

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Treating acute coronary syndromes with new antiplatelet drugs: The mortality issue with prasugrel and ticagrelor'. Together they form a unique fingerprint.

Cite this